Delving into the Latest Updates on Loxapine with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Loxapine (USAN/INN), Staccato Loxapine, ALXZ-004

+ [4]

Target

5-HT2A receptor x D2 receptor

Mechanism

5-HT2A receptor antagonists(Serotonin 2a (5-HT2a) receptor antagonists), D2 receptor antagonists(Dopamine D2 receptor antagonists)

Therapeutic Areas

Other Diseases

Active Indication

AgitationBipolar DisorderBipolar I disorder+ [1]

Inactive Indication

AsthmaCigarette SmokingMigraine Disorders+ [2]

Originator Organization

Alexza Pharmaceuticals, Inc.

Active Organization

Ferrer Internacional SA

Zhaoke Pharmaceutical (Hefei) Co., Ltd.

Alexza Pharmaceuticals, Inc.

Inactive Organization

Lee's Pharmaceutical Holdings Ltd.

Drug Highest PhaseApproved

First Approval Date

US (21 Dec 2012),

Bipolar I disorderSchizophrenia

Regulation-

Login to view First Approval Timeline

Structure

Molecular FormulaC18H18ClN3O

InChIKeyXJGVXQDUIWGIRW-UHFFFAOYSA-N

CAS Registry1977-10-2

People living with dementia commonly experience anxiety, which is often challenging to manage. We investigated the effectiveness of treatments for the management of anxiety in this population. We conducted a systematic review and meta-analysis of randomised controlled trials, and searched EMBASE, CINAHL, MEDLINE and PsycInfo. We estimated standardised mean differences at follow-up between treatments relative to control groups and pooled these across studies using random-effects models where feasible. Thirty-one studies were identified. Meta-analysis demonstrated non-pharmacological interventions were effective in reducing anxiety in people living with dementia, compared to care as usual or active controls. Specifically, music therapy (SMD-1.92(CI:-2.58,-1.25)), muscular approaches (SMD-0.65(CI:-1.02,-0.28)) and stimulating cognitive and physical activities (SMD-0.31(CI:-0.53,-0.09)). Pharmacological interventions with evidence of potential effectiveness included Ginkgo biloba, probiotics, olanzapine, loxapine and citalopram compared to placebo, olanzapine compared to bromazepam and buspirone and risperidone compared to haloperidol. Meta-analyses were not performed for pharmacological interventions due to studies' heterogeneity. This has practice implications when promoting the use of more non-pharmacological interventions to help reduce anxiety among people living with dementia.

01 Feb 2024·Contact dermatitis

DRESS to loxapine and avoidable recurrence with clozapine

Author: Assier, Haudrey ; Matei, Ilaria ; Ingen-Housz-Oro, Saskia ; Hareth, Kamar Bel ; Weill, Amandine

01 Oct 2023·European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology

Antipsychotic use and 28-day mortality in patients hospitalized with COVID-19: A multicenter observational retrospective study.

Article

Author: Limosin, Frédéric ; Hoertel, Nicolas ; Alvarado, Jesús M ; Airagnes, Guillaume ; Peyre, Hugo ; Edán-Sánchez, Alejandro ; Olfson, Mark ; Delcuze, Aude ; Sánchez-Rico, Marina ; Rezaei, Katayoun

Prior research has yielded conflicting results about the potential influence of antipsychotics in patients with COVID-19. In this multicenter retrospective study, we examined the association of antipsychotic use at admission with 28-day all-cause mortality in a sample of 59,021 adult patients hospitalized with COVID-19 from January 2020 to November 2021. In a 1:1 ratio matched analytic sample (N=1,454) accounting for age, sex, hospital, hospitalization period, the Elixhauser Comorbidity Index, other psychotropic medications, medications prescribed according to compassionate use or as part of a clinical trial, current diagnoses of psychiatric disorders, and clinical and biological markers of COVID-19 severity, antipsychotic use was not associated with 28-day mortality [23.5% (N=727) versus 18.6% (N=727); OR=1.16; 95%CI=0.89-1.51; p=0.280]. This association remained non-significant in exploratory analyses across all classes of antipsychotics and individual molecules, except for typical antipsychotics and loxapine, which were significantly linked to increased 28-day mortality, associations likely due to residual indication bias. Contrariwise, antipsychotics prescribed at daily doses higher than 200 mg of chlorpromazine-equivalents might be associated with reduced 28-day mortality when compared to patients not taking antipsychotics in the matched analytic sample [10.4% (N=154) versus 18.6% (N=727); AOR=0.56; 95%CI=0.31-0.96; p=0.040]. These results suggest that antipsychotic use, when prescribed at usual doses, are not be associated with 28-day mortality in patients hospitalized with COVID-19.

2

News (Medical) associated with Loxapine

29 Mar 2023

·www.biospace.com

IntelGenx Reports Fourth Quarter and Full-Year 2022 Financial Results

SAINT LAURENT, Quebec, March 29, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today reported financial results for the three- and twelve-month periods ended December 31, 2022. All dollar amounts are expressed in U.S. currency, unless otherwise indicated, and results are reported in accordance with United States generally accepted accounting principles except where noted otherwise. "The progress we made throughout 2022 has led us to now being potentially on the cusp of a stage of anticipated rapid growth,” commented Dr. Horst G. Zerbe, CEO of IntelGenx. “In April, we expect the FDA’s decisions on the Buprenorphine Buccal Film ANDA, as well as the RIZAFILM® NDA. On the development front, we are also looking forward to atai announcing topline results from its Phase 1 clinical trial of Buccal VLS-01, the first ever in-human clinical study evaluating an all thin film psychedelic drug candidate.” 2022 Fourth Quarter Financial Highlights: Revenue was $173,000, compared to $494,000 in the 2021 fourth quarter, mostly due to one-time licensing revenue received in 2021. Net comprehensive loss was $2.3 million, compared to $2.9 million in the 2021 fourth quarter. Adjusted EBITDA loss was $2.3 million, essentially unchanged from Q4-2021. 2022 Full-Year Financial Highlights: Revenue was $1.0 million, compared to $1.5 million in 2021, mostly due to one-time licensing revenue received in 2021. Net comprehensive loss was $11.6 million, compared to $9.8 million in 2021. Adjusted EBITDA loss was $8.5 million, compared to $7.1 million in 2021. Fourth Quarter and Recent Developments: Received a fourth and final term loan tranche in the amount of $3.0 million pursuant to the amended and restated secured loan agreement with the Company’s strategic partner, atai Life Sciences (“atai’). Closed a private placement offering of convertible notes due March 1, 2027 for aggregate gross proceeds of approximately $760,000 (C$1 million). Received from the U.S. Food and Drug Administration (‘FDA”) a Prescription Drug User Fee Act (PDUFA) goal date of April 17, 2023 for completion of the Agency’s review of the 505(b)(2) New Drug Application (“NDA”) for RIZAFILM® VersaFilm®. Participated in the 35th Annual ROTH Conference in Dana Point, California. Granted a Notice of Allowance for U.S. Patent Application 16/053,383, entitled "Loxapine Film Oral Dosage Form,” from the United States Patent and Trademark Office. Entered into a research collaboration with Per Svenningsson, MD, PhD, of the Karolinska Institute, to plan and conduct a multicentre, randomized, double-blind, placebo-controlled clinical study to investigate the use of Montelukast VersaFilm® for the treatment of Parkinson’s Disease. Entered into an exclusive supply agreement for RIZAPORT® with ARWAN Pharmaceuticals Industries Lebanon s.a.l. in various countries in the Middle East and North Africa region. Entered into a research collaboration with the University of Prince Edward Island to assess palatability, owner-perceived acceptability, and ease of administration of the Company’s VetaFilm™ platform in healthy dogs and cats. Financial Results: Total revenues for the three-month period ended December 31, 2022 amounted to $173,000, a decrease of $321,000, or 65%, compared to $494,000 for the three-month period ended December 31, 2021. The change is mainly attributable to decreases in revenues from licensing agreements of $249,000, R&D revenues of $43,000 and product revenues of $36,000, offset partially by an increase in royalties on product sales of $7,000. Operating costs and expenses were $2.7 million for the fourth quarter of 2022, versus $3.0 million for the corresponding three-month period of 2021. For Q4-2022, the Company had an operating loss of $2.5 million, essentially unchanged from the operating loss for the comparable period of 2021. Net comprehensive loss was $2.3 million, or $0.01 per basic and diluted share, for the fourth quarter of 2022, compared to net comprehensive loss of $2.9 million, or $0.02 per basic and diluted share, for the comparable period of 2021. Total revenues for the twelve-month period ended December 31, 2022 amounted to $1.0 million, representing a decrease of $585,000, or 38%, compared to $1.5 million for the year ended December 31, 2021. Operating costs and expenses were $10.4 million for the full year 2022, versus $9.5 million for the corresponding twelve-month period of 2021. For the twelve-month period of 2022, the Company had an operating loss of $9.4 million, compared to an operating loss of $8.0 million for the comparable period of 2021. Net comprehensive loss was $11.6 million, or $0.07 per basic and diluted share, for the twelve-month period of 2022, compared to net comprehensive loss of $9.8 million, or $0.07 per basic and diluted share, for the comparable period of 2021. As at December 31, 2022, the Company's cash and short-term investments totalled $2.5 million, which did not include the $3.0 million secured loan granted to IntelGenx Corp. by atai in January 2023, nor the $760,000 in gross proceeds from the private placement offering of convertible notes, which closed in March 2023. Annual Filings: The Company's annual report on Form 10-K and financial statements for the year ended December 31, 2022, as well as the 2023 Proxy Statement, will be filed with the United States Securities and Exchange Commission and the Canadian Securities regulatory authorities today, March 29, 2023. Conference Call Details: IntelGenx will host a conference call to discuss these 2022 fourth quarter and full year financial results today at 4:30 p.m. ET. The dial-in number for the conference call is (888) 506-0062 (Canada and the United States) or (973) 528-0011 (International); access code 884881. The call will be also be webcast live and archived on the Company's website at under "Webcasts" in the Investors section. About IntelGenx IntelGenx is a leading drug delivery company focused on the development and manufacturing of pharmaceutical films. IntelGenx’s superior film technologies, including VersaFilm®, DisinteQ™, VetaFilm™ and transdermal VevaDerm™, allow for next generation pharmaceutical products that address unmet medical needs. IntelGenx’s innovative product pipeline offers significant benefits to patients and physicians for many therapeutic conditions. IntelGenx's highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx's state-of-the-art manufacturing facility offers full service by providing lab-scale to pilot- and commercial-scale production. For more information, visit . Forward-Looking Information and Statements This document may contain forward-looking information about IntelGenx's operating results and business prospects that involve substantial risks and uncertainties. Statements that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, but are not limited to, statements about IntelGenx's plans, objectives, expectations, strategies, intentions or other characterizations of future events or circumstances and are generally identified by the words "may," "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "could," "would," and similar expressions. All forward looking statements are expressly qualified in their entirety by this cautionary statement. Because these forward-looking statements are subject to a number of risks and uncertainties, IntelGenx's actual results could differ materially from those expressed or implied by these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the heading "Risk Factors" in IntelGenx's annual report on Form 10-K, filed with the United States Securities and Exchange Commission and available at , and also filed with Canadian securities regulatory authorities at . IntelGenx assumes no obligation to update any such forward-looking statements. Source: IntelGenx Technologies Corp. For IntelGenx: Stephen Kilmer Investor Relations (647) 872-4849 stephen@kilmerlucas.com Or Andre Godin, CPA, CA President and CFO IntelGenx Corp. (514) 331-7440 ext 203 andre@intelgenx.com

Phase 1Financial Statement

29 Jun 2022

·www.biospace.com

Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2022 and Provides Conference Call Information

Conference Call Scheduled for Thursday, June 30 at 11:30 AM EDT NORTHVALE, NJ / ACCESSWIRE / June 29, 2022 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing niche generic products, announced results for the fiscal year ended March 31, 2022 ("Fiscal 2022"). Consolidated revenues for Fiscal 2022 were $32.3 million, an increase of $6.9 million or 27% as compared to the comparable period of the prior fiscal year. The increase was primarily attributed to revenues from generic immediate-release Adderall®, generic extended-release Adderall®, generic Loxapine Capsules, and strong revenues relating to Naltrexone Tablets sales. Operating profits were $5.1 million, an increase of $3.0 million from the comparable period of the prior year, and net income was $8.9 million. Conference Call Information Elite's management will host a conference call to discuss the year-end 2022 financial results and provide an update on recent business developments. Stockholder questions should be submitted to the company in advance of the call. Date: June 30, 2022 Time: 11:30 AM EDT Dial-in numbers: 1-800-346-7359 (domestic) 1-973-528-0008 (international) Conference number: 98840 Questions: dianne@elitepharma.com Financial questions by 7:00 PM EST on Wednesday, June 29, 2022 Audio Replay: The financial statements can be viewed for Elite's Year 2022 on Form 10-K here. About Elite Pharmaceuticals, Inc. Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops niche generic products. Elite specializes in developing and manufacturing oral, controlled-release drug products. Elite owns multiple generic products which have been licensed to Lannett Company, Prasco, LLC, Epic Pharma, LLC, and TAGI Pharma. Elite operates a cGMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ. For more information, visit . This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, those related to the effects, if any, on future results, performance or other expectations that may have some correlation to the subject matter of this press release. Readers are cautioned that such forward-looking statements involve, without limitation, risks, uncertainties and other factors not under the control of Elite, which may cause actual results, performance or achievements of Elite to be materially different from the results, performance or other expectations that may be implied by these forward-looking statements. These forward-looking statements may include statements regarding the expected timing of approval, if at all, of products by the FDA, and the actions the FDA may require of Elite in order to obtain such approvals. These forward-looking statements are not guarantees of future action or performance. These risks and other factors are discussed, without limitation, in Elite's filings with the Securities and Exchange Commission, including its reports on forms 10-K, 10-Q, and 8-K. Elite is under no obligation to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise. Contact: For Elite Pharmaceuticals, Inc. Dianne Will, Investor Relations, 518-398-6222 Dianne@elitepharma.com SOURCE: Elite Pharmaceuticals, Inc. View source version on accesswire.com:

Financial Statement

100 Deals associated with Loxapine

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D02340	Loxapine	N05AH01	DB00408

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Agitation	EU	Ferrer Internacional SA	20 Feb 2013
Agitation	IS	Ferrer Internacional SA	20 Feb 2013
Agitation	LI	Ferrer Internacional SA	20 Feb 2013
Agitation	NO	Ferrer Internacional SA	20 Feb 2013
Bipolar Disorder	EU	Ferrer Internacional SA	20 Feb 2013
Bipolar Disorder	IS	Ferrer Internacional SA	20 Feb 2013
Bipolar Disorder	LI	Ferrer Internacional SA	20 Feb 2013
Bipolar Disorder	NO	Ferrer Internacional SA	20 Feb 2013
Bipolar I disorder	US	Alexza Pharmaceuticals, Inc.	21 Dec 2012
Schizophrenia	US	Alexza Pharmaceuticals, Inc.	21 Dec 2012

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Psychomotor Agitation	Phase 3	-	Lee's Pharmaceutical Holdings Ltd.	01 Dec 2019
Migraine Disorders	Phase 2	US	Alexza Pharmaceuticals, Inc.	01 Jun 2007
Pulmonary Disease, Chronic Obstructive	Phase 1	US	Alexza Pharmaceuticals, Inc.	01 Jun 2009
Asthma	Phase 1	US	Alexza Pharmaceuticals, Inc.	01 May 2009
Cigarette Smoking	Phase 1	US	Alexza Pharmaceuticals, Inc.	01 Apr 2009

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00789360 (CTgov)	Phase 1	-	30	Loxapine (Inhaled Loxapine)	uwwkdndgun(teebbsxyoh) = pyxursyumo bfodpmrbvv (bzhdwxbwnr, vqlimqpxdl - qegelcevfo) View more	-	11 Mar 2019
				Staccato Placebo (Inhaled Staccato Placebo)	uwwkdndgun(teebbsxyoh) = rzrkdjecqu bfodpmrbvv (bzhdwxbwnr, njcgqfoquf - wymmxzynwc)
NCT00444028 (CTgov)	Phase 1	Schizophrenia	50	Staccato Loxapine (Staccato Loxapine 0.625 mg)	ygzytaelex(mhrxvzqmqg) = doltojhqoh exsgeyibpj (wnsllemgcw, mgpiigpeha - harwcjgnsc) View more	-	20 Nov 2018
				Staccato Loxapine (Staccato Loxapine 1.25 mg)	ygzytaelex(mhrxvzqmqg) = ttjahajbpx exsgeyibpj (wnsllemgcw, ijewfeuqzt - bppgaulrfk) View more
NCT03110900 (CTgov)	Phase 4	Drug intoxication \| Psychomotor Agitation \| Agitation	2	lorazepam+Haloperidol (Haloperidol + Lorazepam)	mmrgygvqlq(agtluglrtg) = viwrlzfyub tiqtbsencl (fgravxshmy, nszlnhtrhh - ynqmbwupfd) View more	-	11 Jun 2018
				Loxapine (Loxapine)	mmrgygvqlq(agtluglrtg) = ysebyiqvhd tiqtbsencl (fgravxshmy, xfpozhquby - drrkyudixj) View more
NCT01193816 (Pubmed \| Crit Care)	Phase 4	Agitation	102	Loxapine	asmuclxtnb(dgcxawylyt) = qtlqsspttm cmuwsvhwzq (yuvasrfknu )	-	06 Sep 2017
				Placebo	asmuclxtnb(dgcxawylyt) = hwfzrfpfoj cmuwsvhwzq (yuvasrfknu )
NCT00489476 (CTgov)	Phase 2	Migraine Disorders	168	Staccato Placebo (Staccato Placebo)	oqjaqkyutq(jhqrkefsab) = wcmvgpokuh oobxoransj (wqntpdddev, wjgnzzmfza - onjglgejfo) View more	-	24 Apr 2017
				Staccato Loxapine (1.25 mg Staccato Loxapine)	oqjaqkyutq(jhqrkefsab) = obixmhtdlo oobxoransj (wqntpdddev, qncwrzwvvk - vpbmlwbgqa) View more
NCT00825500 (CTgov)	Phase 2	Migraine Disorders	366	Inhaled Placebo (Inhaled Placebo)	zshkljyqmc(hdzxizwhkz) = ctcfsfuxwl bpfjbjbkcs (cvqnywbvkd, njmuedlmfh - humewdpfeu) View more	-	24 Apr 2017
				Inhaled Loxapine 1.25 mg (Inhaled Loxapine 1.25 mg)	zshkljyqmc(hdzxizwhkz) = khbmuhimmw bpfjbjbkcs (cvqnywbvkd, xwhpimtgcz - zycqpejjvu) View more
Pubmed \| J Aerosol Med Pulm Drug Deliv	Not Applicable	Pulmonary Disease, Chronic Obstructive \| Asthma	-	Inhaled Loxapine 10mg	wunvopwioe(ggzcczboyj) = All airway adverse events (AEs) were of mild or moderate severity ictfuryeft (dhjzafickq ) View more	-	01 Dec 2014
				Placebo
NCT00874237 (Pubmed \| J Clin Pharmacol)	Phase 1	-	48	Inhaled placebo	kdhosrsdde(htuvhkykob) = shcsedxljc zxtnmxjvdf (wrgqnrsxrj ) View more	Negative	01 Jun 2014
				10 mg loxapine	lhehihyfjm(rgkxakterg) = bgmczpwzwt umoqcpryai (xjcrzextln ) View more